VKTX

30.29

2.16% 0.64

Pre-mercato: 30.11 -0.18 -0.59%

Viking Therapeutics Inc (VKTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VKTX Giù? Forum Previsione

Precedente Chiudi:

$29.65

Aprire:

$30

Volume 24 ore:

1.88M

Relative Volume:

0.86

Capitalizzazione di mercato:

$3.52B

Reddito:

Utile/perdita netta:

$-472.34M

Rapporto P/E:

-7.306

EPS:

-4.1459

Flusso di cassa netto:

$-340.33M

1 W Prestazione:

+9.15%

1M Prestazione:

+0.07%

6M Prestazione:

-11.69%

1 anno Prestazione:

+14.60%

Intervallo 1D:

$29.60

$31.27

Intervallo di 1 settimana:

$27.16

$31.27

Portata 52W:

$22.96

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Nome

Viking Therapeutics Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

858-704-4660

Indirizzo

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Dipendente

Cinguettio

@viking_vktx

Prossima data di guadagno

2026-07-22

Ultimi documenti SEC

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VKTX Viking Therapeutics Inc	30.29	3.44B	0	-472.34M	-340.33M	-4.1459
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-26	Iniziato	Wolfe Research	Peer Perform
2025-10-29	Iniziato	Canaccord Genuity	Buy
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-04-08	Iniziato	Goldman	Neutral
2025-02-13	Iniziato	Scotiabank	Sector Outperform
2025-02-07	Iniziato	Citigroup	Neutral
2024-12-02	Iniziato	Piper Sandler	Overweight
2024-11-22	Iniziato	B. Riley Securities	Buy
2024-11-04	Reiterato	H.C. Wainwright	Buy
2024-09-11	Iniziato	JP Morgan	Overweight
2024-06-27	Iniziato	Morgan Stanley	Overweight
2024-05-16	Aggiornamento	Raymond James	Outperform → Strong Buy
2024-03-26	Reiterato	Oppenheimer	Outperform
2024-03-07	Iniziato	Jefferies	Buy
2024-02-28	Reiterato	Oppenheimer	Outperform
2023-05-31	Ripresa	ROTH MKM	Buy
2023-03-28	Reiterato	Maxim Group	Buy
2023-03-17	Iniziato	Stifel	Buy
2021-07-29	Ripresa	BTIG Research	Buy
2021-05-25	Downgrade	Raymond James	Strong Buy → Outperform
2020-06-05	Iniziato	BMO Capital Markets	Outperform
2020-05-05	Iniziato	Chardan Capital Markets	Buy
2020-05-01	Iniziato	BTIG Research	Buy
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-25	Iniziato	Stifel	Buy
2019-03-29	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-03-14	Reiterato	Maxim Group	Buy
2019-02-22	Iniziato	SVB Leerink	Mkt Perform
2018-12-12	Iniziato	B. Riley FBR	Buy
2018-11-19	Aggiornamento	Raymond James	Outperform → Strong Buy
2018-09-18	Reiterato	H.C. Wainwright	Buy
2018-09-18	Reiterato	Maxim Group	Buy
2018-09-18	Reiterato	Raymond James	Outperform
2018-07-20	Iniziato	SunTrust	Buy
2018-06-28	Iniziato	Raymond James	Outperform
2018-06-01	Reiterato	Laidlaw	Buy
2018-05-31	Reiterato	Maxim Group	Buy
2018-03-26	Ripresa	H.C. Wainwright	Buy
2017-11-28	Reiterato	Maxim Group	Buy
2017-11-21	Iniziato	ROTH Capital	Buy

Mostra tutto

Viking Therapeutics Inc Borsa (VKTX) Ultime notizie

Jun 15, 2026

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits

Jun 15, 2026

Jun 14, 2026

VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits

Jun 14, 2026

Jun 13, 2026

VKTX Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 13, 2026

Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm

Jun 13, 2026

Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - simplywall.st

Jun 13, 2026

Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance

Jun 12, 2026

VKTX Stock Price, Quote & Chart - ChartMill

Jun 12, 2026

Is Viking Therapeutics Stock Going to $100? - The Motley Fool

Jun 12, 2026

Jun 11, 2026

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits

Jun 11, 2026

VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits

Jun 11, 2026

Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma

Jun 11, 2026

Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus

Jun 11, 2026

Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com

Jun 11, 2026

Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria

Jun 11, 2026

Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz

Jun 11, 2026

Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com

Jun 11, 2026

Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView

Jun 11, 2026

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - PR Newswire

Jun 11, 2026

Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN

Jun 11, 2026

VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN

Jun 11, 2026

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com

Jun 11, 2026

Jun 10, 2026

Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500

Jun 10, 2026